ClinicalTrialMD

With over a decade of experience in psychiatry and clinical research, Dr. Bhalavat leads ClinicalTrialMD with a deep commitment to advancing mental health treatment.

He serves as a Principal Investigator at American Psychiatric Care, where he has led multiple clinical trials in depression, bipolar disorder, and schizophrenia, including large-scale Phase 3 studies and observational research.

Principal Investigator
March 2025 – Present (1 year 2 months)
Bel Air, MD
NCT06656416

ALTO-100 in Bipolar Disorder With Depression (BD-D)
Phase II: Bipolar Disorder I or II With a Major Depressive Episode

Interventional: Recruiting

Certified Rater:
Montgomery Asberg Depression Rating Scale (MADRS)
Structured Clinical Interview for the DSM-5 (SCID-5-CT)
Young Mania Rating Scale (YMRS)
Bipolar Treatment Response Questionnaire (BTRQ)
Patient Reported Outcome (PRO)
Concise Health Risk Tracking – Clinician-Rated (CHRT-C)
Clinical Global Impression – Severity

Principal Investigator
June 2024 – January 2025 (8 months)
Bel Air, MD
NCT04855760

Safety of REL-1017 for Major Depressive Disorder
REL-1017-302 – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo
Controlled Study to Assess the Efficacy and Safety of REL-1017 for Major
Depressive Disorder (The RELIANCE-II Study) Protocol.

Certified Rater: Montgomery-Åsberg Depression Rating Scale
(MADRS),Clinical Global Impression of Severity (CGI-S),Hamilton Depression
Rating Scale (HAMD17),Antidepressant Treatment Response Questionnaire
(ATRQ) ,Structured Clinical Interview for DSM-5,Hamilton Anxiety Depression
Scale (HAM-A),Symptoms of Depression Questionnaire (SDQ),Sheehan
Disability Scale (SDS) ,Clinical Global Impression of Improvement (CGII),Digit Symbol Substitution Test (DSST),Perceived Deficits Questionnaire –
Depression (PDQ-D-5),Arizona Sexual Experience Scale (ASEX)
Principal Investigator
June 2024 – December 2024 (7 months)
Bel Air, MD
NCT04855760

Safety of REL-1017 for Major Depressive Disorder
Phase III: Major Depressive Disorder
Interventional: Completed
Principal Investigator
January 2018 – December 2018 (1 year)
Bel Air, MD
NCT03919994
Observational Study of Long Acting Injectable Medications (LAIs) in
Schizophrenia (OASIS)
Phase NA: Schizophrenia
Observational: Completed

sub investigator
July 2008 – June 2012 (4 years)
Shreveport, LA
NCT00723450
Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients
Phase III: Bipolar Disorder
Interventional: Completed
NCT00948766

Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in
Patients With Severe Dementia of the Alzheimer’s Type (ACTION) (Study
Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label
Extension to Study CENA713DUS44